Business - Briefly   

Bharat Bio in pact with Acambis

HYDERABAD: Bharat Biotech, Hyderabad, has entered into an agreement with Acambis plc, a Nasdaq listed company, for manufacturing and marketing of Acambis' ChimeriVax, an investigational vaccine against Japanese encephalitis. Bharat Biotech will be responsible for end-stage fill/finish processing of ChimeriVax-JE at its facility in India. Once the vaccine is approved, it will market and distribute the medicine in India and neighbouring countries.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

Centre permits 49 p.c. FDI in ARCs
ITI's second U.P. unit on stream
Disinvestment of equity in non-Navratnas planned
Wockhardt Hospitals gets JCI standards certification
Snow welcomes higher FDI in insurance
EEPC to allot large space to SMEs in Hannover Fair 2006
Metro Group to set up unit in West Bengal
Bombay Rayon price band fixed at Rs. 60-70
AIA Engineering to tap market
Coffee Board differs on Arabica yield
Country headed for timber famine: expert
HLL plans alternative business model to tap export markets
Sensex gives up early gains
Exchange rates
Bullion rates
Demat charges waived from Jan. 9
JSW Signs MoU for steel project
BILT forays into tissue market
GAIL signs MoA with Belgium's Exmar
Sony unveils VAIO notebooks
Satyam, Microsoft China join hands
India Cements' smart turnaround
Empee Sugar sales and profit up
Foundation for SBT Jubilee Bhavan laid
Bharat Bio in pact with Acambis

Copyright © 2005, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu